November 20, 2012 at 21:43 PM EST
Supernus Pharmaceuticals Reports Positive Phase IIb Results on SPN-810 for Treatment of Impulsive Aggression in ADHD Patients
Supernus Pharmaceuticals (NASDAQ: SUPN ) received positive topline results from its Phase IIb study on SPN-810 for the treatment of impulsive aggression in ADHD patients. The study is a multicenter randomized, double-blind, placebo controlled clinical trial in children 6 to 12 diagnosed with Attention Deficit and Hyperactivity Disorder (ADHD) and
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here